Published • loading... • Updated
Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization
The financing will help Rege Nephro pursue global licensing for RN-014 and move RN-032 into nonclinical studies after process development.
- On Tuesday, July 21, 2026, Kyoto-based Rege Nephro Co., Ltd. announced the closing of a US$10.6 million financing round through issuance of J-KISS share acquisition rights to support kidney regenerative medicine development.
- Capital from this round will prioritize commercialization activities for RN-014, a lead candidate for autosomal dominant polycystic kidney disease , and advance nonclinical development of RN-032, an iPS cell-derived regenerative medicine program.
- "This funding round marks an important milestone as we advance RN-014 toward commercialization and accelerate development of RN-032," said Akifumi Morinaka, Representative Director and CEO of Rege Nephro, as the program recently reached Last Patient Last Visit in Phase 2a trials.
- To support continued growth, Rege Nephro will recruit scientific and business development professionals to strengthen its operational foundation while preparing for an anticipated Series C financing round.
- The company leverages scientific discoveries from Professor Kenji Osafune at Kyoto University's Center for iPS Cell Research and Application, positioning itself to develop innovative therapies for patients with difficult-to-treat kidney conditions.
Insights by Ground AI
40 Articles
40 Articles
Coverage Details
Total News Sources40
Leaning Left5Leaning Right7Center25Last UpdatedBias Distribution68% Center
Bias Distribution
- 68% of the sources are Center
68% Center
13%
C 68%
R 19%
Factuality
To view factuality data please Upgrade to Premium
